Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 178

1.

What is the Value of Different Zika Vaccination Strategies to Prevent and Mitigate Zika Outbreaks.

Bartsch SM, Asti L, Cox S, Durham DP, Randall S, Hotez PJ, Galvani AP, Lee BY.

J Infect Dis. 2018 Dec 13. doi: 10.1093/infdis/jiy688. [Epub ahead of print]

PMID:
30544164
2.

Defining control of HIV epidemics.

Galvani AP, Pandey A, Fitzpatrick MC, Medlock J, Gray GE.

Lancet HIV. 2018 Nov;5(11):e667-e670. doi: 10.1016/S2352-3018(18)30178-4. Epub 2018 Oct 9.

PMID:
30314745
3.

Potential effectiveness of long-acting injectable pre-exposure prophylaxis for HIV prevention in men who have sex with men: a modelling study.

Marshall BDL, Goedel WC, King MRF, Singleton A, Durham DP, Chan PA, Townsend JP, Galvani AP.

Lancet HIV. 2018 Sep;5(9):e498-e505. doi: 10.1016/S2352-3018(18)30097-3. Epub 2018 Jun 13.

PMID:
29908917
4.

Policy Lessons From Quantitative Modeling of Leprosy.

Medley GF, Blok DJ, Crump RE, Hollingsworth TD, Galvani AP, Ndeffo-Mbah ML, Porco TC, Richardus JH.

Clin Infect Dis. 2018 Jun 1;66(suppl_4):S281-S285. doi: 10.1093/cid/ciy005.

5.

The Challenge of Vanquishing HIV for the Next Generation-Facing the Future.

Fitzpatrick MC, Gray GE, Galvani AP.

JAMA Pediatr. 2018 Jul 1;172(7):609-610. doi: 10.1001/jamapediatrics.2018.0389. No abstract available.

PMID:
29800028
6.

Optimizing the impact of low-efficacy influenza vaccines.

Sah P, Medlock J, Fitzpatrick MC, Singer BH, Galvani AP.

Proc Natl Acad Sci U S A. 2018 May 15;115(20):5151-5156. doi: 10.1073/pnas.1802479115. Epub 2018 Apr 30.

7.

Evaluating Vaccination Strategies for Zika Virus in the Americas.

Durham DP, Fitzpatrick MC, Ndeffo-Mbah ML, Parpia AS, Michael NL, Galvani AP.

Ann Intern Med. 2018 May 1;168(9):621-630. doi: 10.7326/M17-0641. Epub 2018 Apr 3.

8.

Spatial distribution of leprosy in India: an ecological study.

Grantz KH, Chabaari W, Samuel RK, Gershom B, Blum L, Worden L, Ackley S, Liu F, Lietman TM, Galvani AP, Prajna L, Porco TC.

Infect Dis Poverty. 2018 Mar 27;7(1):20. doi: 10.1186/s40249-018-0402-y.

9.

Dynamic Models of Infectious Disease Transmission in Prisons and the General Population.

Ndeffo-Mbah ML, Vigliotti VS, Skrip LA, Dolan K, Galvani AP.

Epidemiol Rev. 2018 Jun 1;40(1):40-57. doi: 10.1093/epirev/mxx014.

PMID:
29566137
10.

Underestimation of the global burden of schistosomiasis.

King CH, Galvani AP.

Lancet. 2018 Jan 27;391(10118):307-308. doi: 10.1016/S0140-6736(18)30098-9. Epub 2018 Jan 31. No abstract available.

PMID:
29413041
11.

HIV criminalization exacerbates subpar diagnosis and treatment across the United States: response to the 'Association of HIV diagnosis rates and laws criminalizing HIV exposure in the United States'.

Sah P, Fitzpatrick MC, Pandey A, Galvani AP.

AIDS. 2017 Nov 13;31(17):2437-2439. doi: 10.1097/QAD.0000000000001636. No abstract available.

12.

California Universal Health Care Bill: an economic stimulus and life-saving proposal.

Galvani AP, Durham DP, Vermund SH, Fitzpatrick MC.

Lancet. 2017 Oct 28;390(10106):2012-2014. doi: 10.1016/S0140-6736(17)32148-7. Epub 2017 Sep 17. No abstract available.

13.

Saving lives efficiently across sectors: the need for a Congressional cost-effectiveness committee.

Fitzpatrick MC, Singer BH, Hotez PJ, Galvani AP.

Lancet. 2017 Nov 25;390(10110):2410-2412. doi: 10.1016/S0140-6736(17)31440-X. Epub 2017 Jun 29. Review. No abstract available.

14.

Fund global health: Save lives and money.

Galvani AP, Fitzpatrick MC, Vermund SH, Singer BH.

Science. 2017 Jun 9;356(6342):1018-1019. doi: 10.1126/science.aan4683. No abstract available.

15.

Assessing real-time Zika risk in the United States.

Castro LA, Fox SJ, Chen X, Liu K, Bellan SE, Dimitrov NB, Galvani AP, Meyers LA.

BMC Infect Dis. 2017 May 4;17(1):284. doi: 10.1186/s12879-017-2394-9.

16.

The potential economic burden of Zika in the continental United States.

Lee BY, Alfaro-Murillo JA, Parpia AS, Asti L, Wedlock PT, Hotez PJ, Galvani AP.

PLoS Negl Trop Dis. 2017 Apr 27;11(4):e0005531. doi: 10.1371/journal.pntd.0005531. eCollection 2017 Apr.

17.

Characterizing risk of Ebola transmission based on frequency and type of case-contact exposures.

Skrip LA, Fallah MP, Gaffney SG, Yaari R, Yamin D, Huppert A, Bawo L, Nyenswah T, Galvani AP.

Philos Trans R Soc Lond B Biol Sci. 2017 May 26;372(1721). pii: 20160301. doi: 10.1098/rstb.2016.0301.

18.

Effectiveness of UNAIDS targets and HIV vaccination across 127 countries.

Medlock J, Pandey A, Parpia AS, Tang A, Skrip LA, Galvani AP.

Proc Natl Acad Sci U S A. 2017 Apr 11;114(15):4017-4022. doi: 10.1073/pnas.1620788114. Epub 2017 Mar 20.

19.

Forecasting the new case detection rate of leprosy in four states of Brazil: A comparison of modelling approaches.

Blok DJ, Crump RE, Sundaresh R, Ndeffo-Mbah M, Galvani AP, Porco TC, de Vlas SJ, Medley GF, Richardus JH.

Epidemics. 2017 Mar;18:92-100. doi: 10.1016/j.epidem.2017.01.005.

20.

Comparison and validation of two computational models of Chagas disease: A thirty year perspective from Venezuela.

Bartsch SM, Peterson JK, Hertenstein DL, Skrip L, Ndeffo-Mbah M, Galvani AP, Dobson AP, Lee BY.

Epidemics. 2017 Mar;18:81-91. doi: 10.1016/j.epidem.2017.02.004.

21.

Bolstering Community Cooperation in Ebola Resurgence Protocols: Combining Field Blood Draw and Point-of-Care Diagnosis.

Fallah MP, Skrip LA, Raftery P, Kullie M, Borbor W, Laney AS, Blackley DJ, Christie A, Dokubo EK, Lo TQ, Coulter S, Baller A, Vonhm BT, Bemah P, Lomax S, Yeiah A, Wapoe-Sackie Y, Mann J, Clement P, Davies-Wayne G, Hamblion E, Wolfe C, Williams D, Gasasira A, Kateh F, Nyenswah TG, Galvani AP.

PLoS Med. 2017 Jan 24;14(1):e1002227. doi: 10.1371/journal.pmed.1002227. eCollection 2017 Jan.

22.

Global elimination of lymphatic filariasis.

Ndeffo-Mbah ML, Galvani AP.

Lancet Infect Dis. 2017 Apr;17(4):358-359. doi: 10.1016/S1473-3099(16)30544-8. Epub 2016 Dec 22. No abstract available.

23.

One Health approach to cost-effective rabies control in India.

Fitzpatrick MC, Shah HA, Pandey A, Bilinski AM, Kakkar M, Clark AD, Townsend JP, Abbas SS, Galvani AP.

Proc Natl Acad Sci U S A. 2016 Dec 20;113(51):14574-14581. doi: 10.1073/pnas.1604975113.

24.

Philippine drug war and impending public health crisis.

Macarayan E, Ndeffo-Mbah M, Beyrer C, Galvani AP.

Lancet. 2016 Dec 10;388(10062):2870. doi: 10.1016/S0140-6736(16)32468-0. No abstract available.

PMID:
27979404
25.

Human-environment interactions in population and ecosystem health.

Galvani AP, Bauch CT, Anand M, Singer BH, Levin SA.

Proc Natl Acad Sci U S A. 2016 Dec 20;113(51):14502-14506. doi: 10.1073/pnas.1618138113. Epub 2016 Dec 12. No abstract available.

26.

Cost-Effectiveness of Community-Based TB/HIV Screening and Linkage to Care in Rural South Africa.

Gilbert JA, Shenoi SV, Moll AP, Friedland GH, Paltiel AD, Galvani AP.

PLoS One. 2016 Dec 1;11(12):e0165614. doi: 10.1371/journal.pone.0165614. eCollection 2016.

27.

Using Community-Level Prevalence of Loa loa Infection to Predict the Proportion of Highly-Infected Individuals: Statistical Modelling to Support Lymphatic Filariasis and Onchocerciasis Elimination Programs.

Schlüter DK, Ndeffo-Mbah ML, Takougang I, Ukety T, Wanji S, Galvani AP, Diggle PJ.

PLoS Negl Trop Dis. 2016 Dec 1;10(12):e0005157. doi: 10.1371/journal.pntd.0005157. eCollection 2016 Dec.

28.

Optimal frequency of rabies vaccination campaigns in Sub-Saharan Africa.

Bilinski AM, Fitzpatrick MC, Rupprecht CE, Paltiel AD, Galvani AP.

Proc Biol Sci. 2016 Nov 16;283(1842). pii: 20161211.

29.

Vaccination strategies against respiratory syncytial virus.

Yamin D, Jones FK, DeVincenzo JP, Gertler S, Kobiler O, Townsend JP, Galvani AP.

Proc Natl Acad Sci U S A. 2016 Nov 15;113(46):13239-13244. Epub 2016 Oct 31.

30.

Mitigating Prenatal Zika Virus Infection in the Americas.

Ndeffo-Mbah ML, Parpia AS, Galvani AP.

Ann Intern Med. 2016 Oct 18;165(8):551-559. doi: 10.7326/M16-0919. Epub 2016 Jul 26.

PMID:
27454076
31.

Cost-Effectiveness of Rotavirus Vaccination in France-Accounting for Indirect Protection.

Yamin D, Atkins KE, Remy V, Galvani AP.

Value Health. 2016 Sep - Oct;19(6):811-819. doi: 10.1016/j.jval.2016.05.011. Epub 2016 Jul 15.

32.

Pregnancy outcomes in Liberian women who conceived after recovery from Ebola virus disease.

Fallah MP, Skrip LA, Dahn BT, Nyenswah TG, Flumo H, Glayweon M, Lorseh TL, Kaler SG, Higgs ES, Galvani AP.

Lancet Glob Health. 2016 Oct;4(10):e678-9. doi: 10.1016/S2214-109X(16)30147-4. No abstract available.

33.

Next Steps for Ebola Vaccination: Deployment in Non-Epidemic, High-Risk Settings.

Skrip LA, Galvani AP.

PLoS Negl Trop Dis. 2016 Aug 18;10(8):e0004802. doi: 10.1371/journal.pntd.0004802. eCollection 2016 Aug. No abstract available.

34.

Stimulating Influenza Vaccination via Prosocial Motives.

Li M, Taylor EG, Atkins KE, Chapman GB, Galvani AP.

PLoS One. 2016 Jul 26;11(7):e0159780. doi: 10.1371/journal.pone.0159780. eCollection 2016.

35.

Disease Surveillance on Complex Social Networks.

Herrera JL, Srinivasan R, Brownstein JS, Galvani AP, Meyers LA.

PLoS Comput Biol. 2016 Jul 14;12(7):e1004928. doi: 10.1371/journal.pcbi.1004928. eCollection 2016 Jul.

36.

A Cost-Effectiveness Tool for Informing Policies on Zika Virus Control.

Alfaro-Murillo JA, Parpia AS, Fitzpatrick MC, Tamagnan JA, Medlock J, Ndeffo-Mbah ML, Fish D, Ávila-Agüero ML, Marín R, Ko AI, Galvani AP.

PLoS Negl Trop Dis. 2016 May 20;10(5):e0004743. doi: 10.1371/journal.pntd.0004743. eCollection 2016 May.

37.

Cost-Effectiveness of Pertussis Vaccination During Pregnancy in the United States.

Atkins KE, Fitzpatrick MC, Galvani AP, Townsend JP.

Am J Epidemiol. 2016 Jun 15;183(12):1159-70. doi: 10.1093/aje/kwv347. Epub 2016 May 13.

38.

National- and state-level impact and cost-effectiveness of nonavalent HPV vaccination in the United States.

Durham DP, Ndeffo-Mbah ML, Skrip LA, Jones FK, Bauch CT, Galvani AP.

Proc Natl Acad Sci U S A. 2016 May 3;113(18):5107-12. doi: 10.1073/pnas.1515528113. Epub 2016 Apr 18.

39.

Cost-effectiveness of next-generation vaccines: The case of pertussis.

Fitzpatrick MC, Wenzel NS, Scarpino SV, Althouse BM, Atkins KE, Galvani AP, Townsend JP.

Vaccine. 2016 Jun 17;34(29):3405-11. doi: 10.1016/j.vaccine.2016.04.010. Epub 2016 Apr 14.

PMID:
27087151
40.

Evaluating the effectiveness of localized control strategies to curtail chikungunya.

Ndeffo-Mbah ML, Durham DP, Skrip LA, Nsoesie EO, Brownstein JS, Fish D, Galvani AP.

Sci Rep. 2016 Apr 5;6:23997. doi: 10.1038/srep23997.

41.

Epidemiological and Economic Effects of Priming With the Whole-Cell Bordetella pertussis Vaccine.

DeAngelis H, Scarpino SV, Fitzpatrick MC, Galvani AP, Althouse BM.

JAMA Pediatr. 2016 May 1;170(5):459-65. doi: 10.1001/jamapediatrics.2016.0047.

PMID:
27018830
42.

Quantifying Transmission of Clostridium difficile within and outside Healthcare Settings.

Durham DP, Olsen MA, Dubberke ER, Galvani AP, Townsend JP.

Emerg Infect Dis. 2016 Apr;22(4):608-16. doi: 10.3201/eid2204.150455.

43.

Determinants of Human African Trypanosomiasis Elimination via Paratransgenesis.

Gilbert JA, Medlock J, Townsend JP, Aksoy S, Ndeffo Mbah M, Galvani AP.

PLoS Negl Trop Dis. 2016 Mar 8;10(3):e0004465. doi: 10.1371/journal.pntd.0004465. eCollection 2016 Mar.

44.

Retrospective Analysis of the 2014-2015 Ebola Epidemic in Liberia.

Atkins KE, Pandey A, Wenzel NS, Skrip L, Yamin D, Nyenswah TG, Fallah M, Bawo L, Medlock J, Altice FL, Townsend J, Ndeffo-Mbah ML, Galvani AP.

Am J Trop Med Hyg. 2016 Apr;94(4):833-9. doi: 10.4269/ajtmh.15-0328. Epub 2016 Feb 29.

45.

Effects of Response to 2014-2015 Ebola Outbreak on Deaths from Malaria, HIV/AIDS, and Tuberculosis, West Africa.

Parpia AS, Ndeffo-Mbah ML, Wenzel NS, Galvani AP.

Emerg Infect Dis. 2016 Mar;22(3):433-41. doi: 10.3201/eid2203.150977.

46.

Respiratory virus transmission dynamics determine timing of asthma exacerbation peaks: Evidence from a population-level model.

Eggo RM, Scott JG, Galvani AP, Meyers LA.

Proc Natl Acad Sci U S A. 2016 Feb 23;113(8):2194-9. doi: 10.1073/pnas.1518677113. Epub 2016 Feb 8.

47.

Interrupting Ebola Transmission in Liberia Through Community-Based Initiatives.

Fallah M, Dahn B, Nyenswah TG, Massaquoi M, Skrip LA, Yamin D, Mbah MN, Joe N, Freeman S, Harris T, Benson Z, Galvani AP.

Ann Intern Med. 2016 Mar 1;164(5):367-9. doi: 10.7326/M15-1464. Epub 2016 Jan 5. No abstract available.

PMID:
26746879
48.

Quantifying Poverty as a Driver of Ebola Transmission.

Fallah MP, Skrip LA, Gertler S, Yamin D, Galvani AP.

PLoS Negl Trop Dis. 2015 Dec 31;9(12):e0004260. doi: 10.1371/journal.pntd.0004260. eCollection 2015 Dec.

49.

Quantitative analyses and modelling to support achievement of the 2020 goals for nine neglected tropical diseases.

Hollingsworth TD, Adams ER, Anderson RM, Atkins K, Bartsch S, Basáñez MG, Behrend M, Blok DJ, Chapman LA, Coffeng L, Courtenay O, Crump RE, de Vlas SJ, Dobson A, Dyson L, Farkas H, Galvani AP, Gambhir M, Gurarie D, Irvine MA, Jervis S, Keeling MJ, Kelly-Hope L, King C, Lee BY, Le Rutte EA, Lietman TM, Ndeffo-Mbah M, Medley GF, Michael E, Pandey A, Peterson JK, Pinsent A, Porco TC, Richardus JH, Reimer L, Rock KS, Singh BK, Stolk W, Swaminathan S, Torr SJ, Townsend J, Truscott J, Walker M, Zoueva A; NTD Modelling Consortium.

Parasit Vectors. 2015 Dec 9;8:630. doi: 10.1186/s13071-015-1235-1.

50.

Optimizing age of cytomegalovirus screening and vaccination to avert congenital disease in the US.

Alfaro-Murillo JA, Townsend JP, Galvani AP.

Vaccine. 2016 Jan 4;34(2):225-229. doi: 10.1016/j.vaccine.2015.11.039. Epub 2015 Nov 27.

PMID:
26631416

Supplemental Content

Loading ...
Support Center